Short answer
OptimizeRx Corp (OPRX) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $26M (up 22.3% year over year) with net income of $779,000.
Q3 2025 key financials · XBRL
- Revenue
- $26M
- +22.3% YoY · −10.7% QoQ
- Net income
- $779,000
- +108.5% YoY · −49.2% QoQ
- Operating margin
- 7.9%
- Gross margin
- 67.2%
- EPS (diluted)
- $0.05
- +110.0% YoY · −37.5% QoQ
Source: XBRL data from the OptimizeRx Corp (OPRX) Q3 2025 10-Q on SEC EDGAR. USD.
OptimizeRx Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $26.067M, up 22% from $21.309M, driven by DTC and DAAP sales
- Gross margin 67.2% vs 63.1%; operating margin 7.9% vs (40.2)% YoY
- Best-performing offerings DTC and DAAP, cited as revenue-growth drivers without separate figures
- Operating cash flow $11.627M vs $4.691M; financing cash use $5.350M vs $2.087M
- Outlook: operations and existing cash expected to fund obligations for 12 months; macroeconomic uncertainty and customer-demand risks remain
Risk Factors
- No material changes from the December 31, 2024 Form 10-K risk factors
- No newly added risk factor or triggering event disclosed
- No operational, competitive, or market risk updates disclosed
- No liquidity, debt, currency, or concentration risk updates disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OptimizeRx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.